Jul 2026· Journal of AAPOS· pp.
104901
· 1 citation
Medicine
TL;DR
Luminopia demonstrated significant improvements in Registry patients with severe amblyopia, particularly in treatment-naive patients, supporting its use as a viable treatment option that may address key limitations of traditional approaches.
Abstract
Background
Occlusion therapy for severe amblyopia is challenging because of low visual function of the unoccluded eye and lengthy duration of daily therapy, which may then be hindered by low adherence. This study evaluates real-world effectiveness of a binocular digital treatment in patients with severe amblyopia.
Methods
The records of children <18 years with best-corrected visual acuity (BCVA) of 20/100 or worse in their amblyopic eye who were prescribed Luminopia in the PUPiL Registry were retrospectively analyzed. The treatment utilizes contrast reduction and dichoptic masking overlayed on patient-selected programming. Primary outcome was BCVA improvement from baseline to last follow-up. Secondary outcomes included associations between BCVA improvement and total treatment hours, prior amblyopia treatment, age, and amblyopia type. Statistical analyses included correlation, t tests, and regression analyses.
Results
In 57 children with severe amblyopia (mean age, 7.1 ± 2.6 years), mean BCVA improved 1.8 lines (95% CI, 1.0-2.6), with average treatment of 166 hours over 11.8 months. Of the 57 patients, 26 (46%) achieved ≥2-line gains. Treatment-naive patients showed greater improvement (n = 7; 4.4 lines [95% CI, 2.1-6.7]) versus previously treated patients (n = 50; 1.5 lines [95% CI, 0.6-2.3; P = 0.0183]). Worse baseline BCVA (Spearman r = 0.33, P = 0.013) and greater treatment hours (Spearman r = 0.51, P < 0.001), but not age or amblyopia type, were associated with greater BCVA improvement.
Conclusions
Luminopia demonstrated significant improvements in Registry patients with severe amblyopia, particularly in treatment-naive patients, supporting its use as a viable treatment option that may address key limitations of traditional approaches.
Vision therapy can produce clinically meaningful and durable visual improvements in amblyopic patients who no longer respond to occlusion alone, and supports extending amblyopia treatment into adolescence and adulthood, while emphasizing the need for tailored approaches based on the etiology of amblyopia and age.
Hassan Hashemi, Alireza Jamali, E. Jafarzadehpur et al.· Strabismus· 0 citations
Administering vision therapy in conjunction with patching significantly improved VA, stereo acuity, and accommodation facility in bilateral refractive amblyopia compared to patching alone.
Saeedeh Hoseinmenni, S. Rahmani, Ebrahim Jafarzadehpour et al.· Journal of Ophthalmic & Visi...· 0 citations
Use of a dichoptic digital therapeutic device in the treatment and management of amblyopia holds exciting potential in deprivation amblyopia, although a percentage of patients with severe amblyopia did show modest improvement.
W. Sambhariya, Courtney L. Kraus· Journal of pediatric ophthal...· 0 citations
Overall, CureSight was noninferior to patching in these amblyopia types and yielded better visual outcomes in children completing ≥ 60% dosage, supporting binocular therapy as an additional first-line option.
O. Yehezkel, T. Wygnanski-Jaffe, B. Kushner et al.· Scientific Reports· 0 citations
Active vision therapy leads to significant and accelerates improvements in CS among children with bilateral refractive amblyopia and demonstrates a rate of change in monocular CS of 0.05 during follow-up time.
Saeed Rahmani, Saeedeh Hoseinmenni, C. Dehghani et al.· International Journal of Oph...· 0 citations
The effect of full cycloplegic spectacle correction on best corrected visual acuity (BCVA), interocular difference in BCVA, and the presence of stereopsis in children previously treated for ametropic amblyopia in children previously diagnosed and treated for amblyopia is evaluated.
Matej Gajdoš, Zuzana Tóthová, Karolína Benca-Kapitánová et al.· Czech and Slovak Ophthalmolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.